The Crohn’s Disease market size was valued at USD 11.1 billion in 2022 and is projected to grow from USD 11.5 Billion in 2023 to USD 15.37 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.7% during the forecast period (2023 - 2032).
Crohn's disease is a type of inflammatory bowel disease (IBD), caused by a combination of environmental, immune, and bacterial factors in genetically prone individuals. There are no medications, drugs or surgical procedures that can cure or prevent Crohn's disease. It is expected that the disease affects about 3.2 per 1,000 people in Europe and North America. It is less common in Asia and Africa. Rates have, however, been growing, particularly in the developing world, since last few years.
The Crohn’s & Colitis Foundation of America (CCFA) stated that over 1 million Americans were diagnosed with Crohn's & ulcerative colitis disorders and diseases, with maximum of them aged above 30. Increasing occurrence of Crohn's disease market has triggered a vigorous demand for its therapeutics. A survey conducted by the US Centre for Disease Control (CDC) has discovered that the incidence rate of Crohn's disease in the country is 3.1 to 14.6 new cases per 100,000 population annually.
North America is expected to account for the largest share of the global Crohn’s disease Market report in 2016, followed by Europe, the region will continue to lead the pack during the forecast period. The emerging markets of China and India will also play a key role in driving growth in the long term, primarily due to the anticipated strong uptake of Remicade over the forecast period.
The disease is highly predominant in developed countries, especially in individuals who smoke and consume alcohol.
Major factors leading to the growth of the market includes higher preference for symptomatic therapeutic, better treatment of inflammatory bowel diseases, arrival of enhanced drugs and healthier investments in R&D programs. High cost of treatment and lack of early diagnosis techniques are the major factor restricting the market growth.
Market Segmentation:
Global Crohn’s Disease Market is segmented based on procedures and drug type. Based on procedures, the market is segmented into Colonoscopy, flexible Sigmoidoscopy, Computerized Tomography (CT), surface coil magnetic resonance imaging (MRI), Capsule Endoscopy, Double-Balloon Endoscopy, Small Bowel Imaging. Colonoscopy due to high efficiency and accuracy is expected to command the largest market share during the forecasted period. Further based on drug type the market is classified into antibiotics, anti-diarrheal, immune system suppressors, pain relievers, and anti-inflammatory drugs. Antibiotics are expected to command the largest market share while anti-inflammatory drugs are expected to grow at the highest CAGR during the forecasted period.
Crohn’s Disease Market Players
The Crohn’s disease market players profiled in the report are Allergan, Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, and Bayer AG, UCB S.A., Perrigo Company plc, Pfizer Inc., Johnson & Johnson Services, Inc., Ferring B.V.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com